Acyclovir and Hydrocortisone
Brand Names: Xerese
Methodology & AI Transparency ⓘ
Acyclovir and Hydrocortisone Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage xerese:, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older).
- 2 Real-world patient consensus: Real-world cohort score of 84% across 20 de-identified Acyclovir and Hydrocortisone entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $12.83 mail/discount cash up to $34.83 uninsured retail (federal NADAC $0.1070).
- 4 Top reported side effects / signs: Most commonly reported Acyclovir and Hydrocortisone tolerability events: application-site irritation (8%), nausea (8.6%), headache (8.2%).
Ask our AI Specialists anything about Acyclovir and Hydrocortisone
Acyclovir and Hydrocortisone Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage xerese:, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older).
12.1 Mechanism of Action Acyclovir is an antiviral drug active against α-herpesviruses and hydrocortisone is an anti-inflammatory drug . As an active herpes simplex virus nucleoside analog dna polymerase inhibitor moiety (Bausch Health US LLC), Acyclovir and Hydrocortisone modulates physiological signaling proportional to 50 mg/g / 10 mg/g Cream exposure and hepatorenal clearance (SPL 2020-08-03).
Following administration (50 mg/g / 10 mg/g Cream), Acyclovir and Hydrocortisone achieves < 5% transdermal or mucosal systemic uptake from Acyclovir and Hydrocortisone bioavailability and initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (acyclovir and hydrocortisone) onset, governed by a Negligible circulating terminal half-life following local Acyclovir and Hydrocortisone application terminal half-life through local esterase/enzymatic cleavage of acyclovir and hydrocortisone with minimal hepatic cytochrome burden.
Before initiating Acyclovir and Hydrocortisone at 50 mg/g / 10 mg/g Cream, clinical safety checklists rule out previous anaphylactoid or exfoliative reaction attributed to acyclovir and hydrocortisone; clinical scenarios where herpes simplex virus nucleoside analog dna polymerase inhibitor exposure from acyclovir and hydrocortisone poses unacceptable risk. Logged tolerability patterns center on nausea (8.6% of reports), headache (8.2% of reports), application-site irritation (8% of reports).
Verify medication reconciliation lists so Acyclovir and Hydrocortisone is not inadvertently duplicated with another herpes simplex virus nucleoside analog dna polymerase inhibitor.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Acyclovir and Hydrocortisone dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Acyclovir and Hydrocortisone
- Clinical scenarios where herpes simplex virus nucleoside analog dna polymerase inhibitor exposure from Acyclovir and Hydrocortisone poses unacceptable risk
Logged Side-Effect Incidence (20 Reports)
Acyclovir and Hydrocortisone Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acyclovir and Hydrocortisone)
Human clinical trial evidence for Acyclovir and Hydrocortisone is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Acyclovir and Hydrocortisone Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1070/unit (~$3.21/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.83 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $12.83 / mo | View logs ↓ |
Acyclovir and Hydrocortisone Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Acyclovir and Hydrocortisone RxNorm Concept ID | 998422 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1070 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.83 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $12.83 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Acyclovir and Hydrocortisone Patient Community, Cohort Filters & Dosage Logs
Cross-verified Acyclovir and Hydrocortisone (herpes simplex virus nucleoside analog dna polymerase inhibitor) monograph synthesizing RxNorm 998422, openFDA FAERS signals, and $12.83–$34.83 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Acyclovir and Hydrocortisone community threads and patient logs by age, biological sex, dosage, and treatment duration.